Hakon Leffler
31 – 40 of 179
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
- Contribution to journal › Article
-
Mark
Installation of O-glycan sulfation capacities in human HEK293 cells for display of sulfated mucins
- Contribution to journal › Article
-
Mark
Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors
- Contribution to journal › Article
-
Mark
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB
- Contribution to journal › Article
-
Mark
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia
- Contribution to journal › Article
-
Mark
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
- Contribution to journal › Article
- 2021
-
Mark
Synthesis and Biological Studies of O3-Aryl Galactosides as Galectin Inhibitors
- Contribution to journal › Article
-
Mark
Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression
- Contribution to journal › Article
-
Mark
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
- Contribution to journal › Article
-
Mark
Entropy–Entropy Compensation between the Protein, Ligand, and Solvent Degrees of Freedom Fine-Tunes Affinity in Ligand Binding to Galectin-3C
- Contribution to journal › Article
